Better Buy: CRISPR Therapeutics vs. Editas Medicine

Over the past year, shares of gene-editing companies Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) have shot up 129% and 212%, respectively. Their mouth-watering returns make the S&P 500's incredibly jump of 17% (during a fraught economic period and public health crisis, no less) look relatively puny.

As we enter the golden age of biotech, it could pay off to invest in the most innovative technologies and companies in the sector. Both firms are focusing their efforts on treating rare genetic disorders, and CRISPR is also specializing in immuno-oncology. Let's see if Editas or CRISPR Therapeutics has the better risk-reward potential.

Source Fool.com